# Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema

> **NCT04600362** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Technical University of Munich** · enrollment: 70 (estimated)

## Conditions studied

- Nummular Eczema

## Interventions

- **DRUG:** Experimental: Dupilumab 300 MG/2 ML Subcutaneous Solution [DUPIXENT]

## Key facts

- **NCT ID:** NCT04600362
- **Lead sponsor:** Technical University of Munich
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-03-30
- **Primary completion:** 2025-09-01
- **Final completion:** 2027-01-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-09-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04600362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04600362, "Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04600362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*